Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunotherapeutic strategies for EBV-associated malignancies.

Trends in molecular medicine - 1 Jun 2001

Khanna R, Tellam J, Duraiswamy J, Cooper L

Abstract excerpt

Advances in our understanding of the role of cytotoxic T lymphocytes (CTLs) in the control of Epstein-Barr virus (EBV)-associated malignancies and the overall biology of these diseases have led to the development of novel therapeutic strategies designed to specifically target viral antigens expressed in these malignancies. Long-term success of many of these strategies is constrained by the latency phenotypes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adoptive Transfer
Share to Burkitt Lymphoma
Share to Carcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Herpesvirus 4, Human

Share to Hodgkin Disease

Share to Immunotherapy

Share to Nasopharyngeal Neoplasms

Share to Neoplasms

Source

Identifiers

PMID: 11378517
DOI: 10.1016/s1471-4914(01)02002-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunotherapeutic strategies for EBV-associated malignancies.PMID 11378517Read ↗

Virally targeted therapies for EBV-associated malignancies.Semantic proximity Read ↗

Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation.Semantic proximity Read ↗

Progress in Prophylactic and Therapeutic EBV Vaccine Development Based on Molecular Characteristics of EBV Target AntigensSemantic proximity Read ↗

Epstein-Barr virus-associated posttransplant lymphoproliferative disorders: new insights in pathogenesis, classification and treatmentSemantic proximity Read ↗

Generation of EBV-specific CTLs suitable for adoptive immunotherapy of EBV-associated lymphoproliferative disease following allogeneic transplantation.Semantic proximity Read ↗

Epstein–Barr virus infection: basis of malignancy and potential for therapySemantic proximity Read ↗

Cytotoxic T Lymphocytes Simultaneously Targeting Multiple Tumor-associated Antigens to Treat EBV Negative LymphomaSemantic proximity Read ↗

HUMAN CYTOTOXIC T LYMPHOCYTE RESPONSES TO EPSTEIN-BARR VIRUS INFECTIONSemantic proximity Read ↗

Redirecting T Cells against Epstein–Barr Virus Infection and Associated OncogenesisSemantic proximity Read ↗

Posttransplant Lymphoproliferative DisordersSemantic proximity Read ↗

TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignanciesSemantic proximity Read ↗

Therapies based on targeting Epstein‐Barr virus lytic replication for EBV ‐associated malignanciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.